Prab: CSV import

2025-02-13T03:52:10Z

CSV import

← Older revision		Revision as of 03:52, 13 February 2025
Line 1:		Line 1:
	~~{{intro}}~~		== Simeprevir ==
	Simeprevir ~~is an oral, direct acting hepatitis C virus (HCV) protease inhibitor that is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotypes 1 and 4.~~

	~~{{livtox}}~~		[[File:Simeprevir.svg\|thumb\|right\|Chemical structure of Simeprevir]]
	Simeprevir ~~has been linked to isolated, rare instances~~ of ~~mild, acute [[liver injury~~]] ~~during treatment and to occasional cases of hepatic decompensation in patients with preexisting cirrhosis.~~

	~~{{history}}~~		'''Simeprevir''' is an [[antiviral drug]] used in the treatment of [[hepatitis C]], a viral infection that affects the liver. It is classified as a [[protease inhibitor]], specifically targeting the [[NS3/4A protease]] of the hepatitis C virus (HCV). Simeprevir is used in combination with other medications to enhance its efficacy in clearing the virus from the body.
	~~The~~ hepatitis C ~~virus is~~ a ~~small RNA virus~~ that is a ~~major cause of chronic hepatitis~~, ~~cirrhosis and hepatocellular carcinoma in~~ the ~~United States as well as worldwide. Various approaches to antiviral therapy~~ of ~~chronic~~ hepatitis C ~~have been developed, starting in the 1980s with interferon alfa which was replaced in the 1990s by long acting forms of interferon~~ (~~peginterferon~~)~~, to which was added the oral nucleoside analogue, ribavirin~~. ~~Between 2010 and 2015, several potent oral, direct acting anti-HCV agents were developed and combinations of these found~~ to ~~have marked activity against~~ the virus, allowing for highly effective therapy without use of interferon with treatment courses of 12 to 24 weeks only. These direct acting agents included HCV protease (NS3/4) inhibitors, structural replication complex (NS5A) inhibitors and the ~~HCV RNA polymerase (NS5B) inhibitors~~.

	~~{{moa}}~~		== Mechanism of Action ==
	~~The HCV protease inhibitors block the activity~~ of the viral encoded protease that is essential in the posttranslational modification of the viral polypeptide, cleaving it into a series of structural and nonstructural (NS: enzyme) regions. The HCV proteases that have been developed are polypeptide-like molecules, modified amino acids that that resemble the specific amino acid sequence that the protease cleaves and act as competitive inhibitors of the protease enzyme. At least four HCV protease inhibitors (all having the suffix: previrs) have been approved for use in the United States: boceprevir [2012], telaprevir [2012], simeprevir [2013] and paritaprevir [2014].

	Simeprevir ~~(sim e' pre vir) was~~ the ~~third HCV~~ protease ~~inhibitor to become clinically available~~ for ~~therapy~~ of hepatitis C. ~~Like other HCV protease inhibitors~~, simeprevir ~~blocks~~ the ~~activity of~~ the viral ~~encoded protease (HCV nonstructural [NS] region 3/4) that is essential~~ in the ~~posttranslational modification~~ of the ~~viral polypeptide that is cleaved into a series of structural and nonstructural (enzyme) regions. When~~ used ~~by itself, it results~~ in ~~rapid inhibition of HCV RNA levels, but resistance develops rapidly in a high proportion of patients. When combined~~ with ~~peginterferon and ribavirin, it was shown to provide a sustained inhibition of HCV RNA with a low rate of~~ antiviral resistance. When given for 24 to 48 weeks, triple therapy using simeprevir increased the sustained virological response (SVR) rate from 40% to 50% (peginterferon and ribavirin alone) to 65% to 75% in patients with genotype 1. Even higher rates of response were found when simeprevir was combined with the HCV polymerase inhibitor sofosbuvir in an all-oral, interferon free regimen for 12 weeks.		Simeprevir works by inhibiting the NS3/4A protease, an enzyme critical for the replication of the hepatitis C virus. By blocking this enzyme, simeprevir prevents the virus from multiplying, thereby reducing the viral load in the patient's body. This action helps in the clearance of the virus when used in combination with other antiviral agents.

	~~{{fda}}~~		== Clinical Use ==
	~~{{PAGENAME}} was approved~~ for use in ~~the United States in 2013 for patients~~ with chronic hepatitis C, ~~genotypes~~ 1 ~~and 4,~~ in combination with peginterferon and ~~ribavirin or as an all-oral regimen with sofosbuvir~~. Simeprevir is ~~available in 150 mg capsules under~~ the ~~brand name Olysio (formerly TMC435),~~ and the ~~recommended dose~~ is ~~150 mg once daily~~ for ~~12 weeks~~. Common side effects include [[rash]], photosensitivity, pruritus, [[nausea]], [[~~headache~~]]~~, muscle aches and abdominal discomfort~~.
	~~{{hepatitis c~~ drugs}}		Simeprevir is indicated for use in adults with chronic hepatitis C infection, particularly those with genotype 1. It is often used in combination with other antiviral drugs such as [[sofosbuvir]] or [[ribavirin]], and sometimes with [[peginterferon alfa]]. The combination therapy is tailored based on the patient's specific genotype and liver function status.
	~~{{coststubd}}~~
			== Administration and Dosage ==

			Simeprevir is administered orally, typically once daily. The dosage and duration of treatment depend on the combination regimen and the patient's response to therapy. It is important for patients to adhere to the prescribed regimen to achieve optimal results.

			== Side Effects ==

			Common side effects of simeprevir include [[rash]], [[photosensitivity]], [[pruritus]], and [[nausea]]. Patients are advised to avoid excessive sun exposure and to use protective measures such as sunscreen and clothing. Serious side effects are rare but can include [[liver dysfunction]] and [[allergic reactions]].

			== Drug Interactions ==

			Simeprevir can interact with other medications, particularly those metabolized by the [[cytochrome P450]] enzyme system. It is important for healthcare providers to review a patient's medication list to avoid potential interactions that could affect the efficacy or safety of the treatment.

			== Related Pages ==

			* [[Hepatitis C]]
			* [[Antiviral drug]]
			* [[Protease inhibitor]]
			* [[Sofosbuvir]]
			* [[Ribavirin]]

			[[Category:Antiviral drugs]]
			[[Category:Hepatitis treatments]]

Prab: Created page with "{{intro}} Simeprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor that is used in combination with other antiviral agents in the treatment of chronic h..."

2019-05-01T20:37:30Z

Created page with "{{intro}} Simeprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor that is used in combination with other antiviral agents in the treatment of chronic h..."

New page

{{intro}}
Simeprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor that is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotypes 1 and 4.

{{livtox}}
Simeprevir has been linked to isolated, rare instances of mild, acute [[liver injury]] during treatment and to occasional cases of hepatic decompensation in patients with preexisting cirrhosis.

{{history}}
The hepatitis C virus is a small RNA virus that is a major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma in the United States as well as worldwide. Various approaches to antiviral therapy of chronic hepatitis C have been developed, starting in the 1980s with interferon alfa which was replaced in the 1990s by long acting forms of interferon (peginterferon), to which was added the oral nucleoside analogue, ribavirin. Between 2010 and 2015, several potent oral, direct acting anti-HCV agents were developed and combinations of these found to have marked activity against the virus, allowing for highly effective therapy without use of interferon with treatment courses of 12 to 24 weeks only. These direct acting agents included HCV protease (NS3/4) inhibitors, structural replication complex (NS5A) inhibitors and the HCV RNA polymerase (NS5B) inhibitors.

{{moa}}
The HCV protease inhibitors block the activity of the viral encoded protease that is essential in the posttranslational modification of the viral polypeptide, cleaving it into a series of structural and nonstructural (NS: enzyme) regions. The HCV proteases that have been developed are polypeptide-like molecules, modified amino acids that that resemble the specific amino acid sequence that the protease cleaves and act as competitive inhibitors of the protease enzyme. At least four HCV protease inhibitors (all having the suffix: previrs) have been approved for use in the United States: boceprevir [2012], telaprevir [2012], simeprevir [2013] and paritaprevir [2014].

Simeprevir (sim e' pre vir) was the third HCV protease inhibitor to become clinically available for therapy of hepatitis C. Like other HCV protease inhibitors, simeprevir blocks the activity of the viral encoded protease (HCV nonstructural [NS] region 3/4) that is essential in the posttranslational modification of the viral polypeptide that is cleaved into a series of structural and nonstructural (enzyme) regions. When used by itself, it results in rapid inhibition of HCV RNA levels, but resistance develops rapidly in a high proportion of patients. When combined with peginterferon and ribavirin, it was shown to provide a sustained inhibition of HCV RNA with a low rate of antiviral resistance. When given for 24 to 48 weeks, triple therapy using simeprevir increased the sustained virological response (SVR) rate from 40% to 50% (peginterferon and ribavirin alone) to 65% to 75% in patients with genotype 1. Even higher rates of response were found when simeprevir was combined with the HCV polymerase inhibitor sofosbuvir in an all-oral, interferon free regimen for 12 weeks.

{{fda}}
{{PAGENAME}} was approved for use in the United States in 2013 for patients with chronic hepatitis C, genotypes 1 and 4, in combination with peginterferon and ribavirin or as an all-oral regimen with sofosbuvir. Simeprevir is available in 150 mg capsules under the brand name Olysio (formerly TMC435), and the recommended dose is 150 mg once daily for 12 weeks. Common side effects include [[rash]], photosensitivity, pruritus, [[nausea]], [[headache]], muscle aches and abdominal discomfort.
{{hepatitis c drugs}}
{{coststubd}}

Simeprevir - Revision history

Prab: CSV import

Prab: Created page with "{{intro}} Simeprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor that is used in combination with other antiviral agents in the treatment of chronic h..."